Quantitative Investment Management LLC Decreases Stock Position in Eli Lilly and Company $LLY

Key Points

• Quantitative Investment Management LLC cut its Eli Lilly stake by 56.5% in the second quarter, selling 5,507 shares and retaining 4,235 shares valued at approximately $5.1 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 and revenue of $22.97 billion, surpassing analyst expectations; revenue increased 47.7% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $1,292.18.
• The company is expanding beyond its obesity franchise by agreeing to acquire Merida Biosciences for up to $2.88 billion, while also advancing its broader drug pipeline. Shares recently traded at $1,147.06, below the consensus target, but the stock carries a premium valuation with a P/E ratio of 38.49.

Quantitative Investment Management LLC cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 56.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,235 shares of the company's stock after selling 5,507 shares during the quarter. Quantitative Investment Management LLC's holdings in Eli Lilly and Company were worth $5,079,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Ancora Advisors LLC raised its stake in shares of Eli Lilly and Company by 15.6% in the second quarter. Ancora Advisors LLC now owns 3,182 shares of the company's stock worth $3,817,000 after purchasing an additional 430 shares during the last quarter. Two Sigma Securities LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $1,614,000. Benjamin Edwards Inc. raised its position in Eli Lilly and Company by 11.5% in the 2nd quarter. Benjamin Edwards Inc. now owns 29,114 shares of the company's stock worth $34,935,000 after buying an additional 3,003 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Eli Lilly and Company during the 2nd quarter valued at about $688,000. Finally, Flputnam Investment Management Co. boosted its holdings in shares of Eli Lilly and Company by 20.1% during the 2nd quarter. Flputnam Investment Management Co. now owns 88,942 shares of the company's stock valued at $106,680,000 after acquiring an additional 14,860 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,147.06 on Friday. The business has a 50-day simple moving average of $1,191.71 and a two-hundred day simple moving average of $1,069.67. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $712.05 and a 52 week high of $1,292.65. The stock has a market cap of $1.08 trillion, a price-to-earnings ratio of 38.49, a PEG ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 23.22%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Merida Biosciences for up to $2.88 billion, its 13th deal of the year. The transaction adds an early-stage immunology platform designed to selectively eliminate disease-causing autoantibodies while preserving normal immune function. Investors may view the acquisition as a way to diversify beyond Mounjaro and Zepbound and build longer-term growth in autoimmune and allergic diseases. Lilly looks beyond obesity with $2.88B autoimmune buyout
• Positive Sentiment: Lilly’s deal activity has outpaced other major pharmaceutical companies this year, reinforcing management’s efforts to replenish and broaden its pipeline. The strategy could reduce reliance on the obesity market over time, although many acquired programs remain early stage. This week in charts: China deals, stock flatlines and Lilly’s M&A spree
• Positive Sentiment: A Lilly subsidiary reached a late-stage development milestone involving an orexin receptor 2 agonist portfolio, triggering an $8.6 million payment to partner Nxera Pharma. The milestone provides evidence of pipeline progress, though the financial impact is modest relative to Lilly’s scale. Nxera Pharma milestone payment
• Neutral Sentiment: Local officials approved the final land-development plan for Lilly’s pharmaceutical plant in Upper Macungie, Pennsylvania. The step supports future manufacturing capacity and jobs but is unlikely to materially affect near-term earnings. Upper Macungie approves Lilly development plan
• Negative Sentiment: LLY is down about 2.7% since its latest earnings report, suggesting investors have been taking profits or looking for additional catalysts after the results. The quarter itself was strong—earnings and revenue exceeded expectations and revenue grew 47.7% year over year—but the stock’s premium valuation leaves limited room for disappointment. Lilly down since last earnings report
• Negative Sentiment: Superluminal Medicines raised $60 million to advance an early-stage MC4R obesity treatment. Although years from commercialization, additional funding for competing obesity therapies highlights the potential for greater competition around Lilly’s core growth market. Superluminal advances rare obesity therapy

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. BMO Capital Markets upgraded shares of Eli Lilly and Company from an "outperform" rating to a "buy" rating in a research report on Tuesday. Wolfe Research reaffirmed an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Guggenheim upped their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Berenberg Bank raised their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research report on Monday, June 22nd. Finally, Royal Bank Of Canada boosted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source